Immuron Plans Phase 2 Trial for IMM-529 following FDA review

Stock Information for Biolargo Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Biolargo Inc

Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now
Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
Immuron announces record Travelan® sales globally, Australia and USA
Immuron requests pre-IND meeting for IMM-529 with FDA filing
Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.